Lipid-lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Mar 2023| TMR3860A| Transparency

Report Highlights

Lipid-lowering Drugs Market – Scope of Report

TMR’s report on the global lipid-lowering drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid-lowering drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid-lowering drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lipid-lowering drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid-lowering drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid-lowering drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid-lowering drugs market.

The report delves into the competitive landscape of the global lipid-lowering drugs market. Key players operating in the global lipid-lowering drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid-lowering drugs market profiled in this report.

Key Questions Answered in Global Lipid-lowering Drugs Market Report

  • What is the sales/revenue generated by lipid-lowering drugs across all regions during the forecast period?
  • What are the opportunities in the global lipid-lowering drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Report Synopsis

Report Metrics Details
Base year considered 2023
Forecast period considered 2023-2031
Units considered $ Million
Segments covered By Drug Class, By Distribution Channel, By Region
Industry covered Pharmaceutical
Countries covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies studied
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Viatris (Mylan N.V.)
  • Dr. Reddy’s Laboratories Ltd.

Lipid-lowering Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global lipid-lowering drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lipid-lowering drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid-lowering drugs market.

  • Table 1 : Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 2 : Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by 2017‒2031, by Indication
  • Table 3 : Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 4 : Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
  • Table 5 : North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
  • Table 6 : North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 7 : North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
  • Table 8 : North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 9 : Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
  • Table 10 : Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 11 : Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
  • Table 12 : Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 13 : Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 14 : Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 15 : Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
  • Table 16 : Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 17 : Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18 : Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 19 : Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
  • Table 20 : Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 21 : Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22 : Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 23 : Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
  • Table 24 : Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Figure 1 : Global Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 2 : Global Lipid-lowering Drugs Market Value Share, by Drug Class, 2021
  • Figure 3 : Global Lipid-lowering Drugs Market Value Share, by Indication, 2021
  • Figure 4 : Global Lipid-lowering Drugs Market Value Share, by Distribution Channel, 2021
  • Figure 5 : Global Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 6 : Global Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 7 : Global Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 8 : Global Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 9 : Global Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 10 : Global Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 11 : Global Lipid-lowering Drugs Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 12 : Global Lipid-lowering Drugs Market Attractiveness Analysis, by Region, 2022–2031
  • Figure 13 : North America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 14 : North America Lipid-lowering Drugs Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 15 : North America Lipid-lowering Drugs Market Attractiveness Analysis, by Country, 2022–2031
  • Figure 16 : North America Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 17 : North America Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 18 : North America Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 19 : North America Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 20 : North America Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 21 : North America Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 22 : Europe Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 23 : Europe Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 24 : Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 25 : Europe Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 26 : Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 27 : Europe Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 28 : Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 29 : Europe Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 30 : Europe Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 31 : Asia Pacific Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 32 : Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 33 : Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 34 : Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 35 : Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 36 : Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 37 : Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 38 : Asia Pacific Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 39 : Asia Pacific Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 40 : Latin America Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 41 : Latin America Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 42 : Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 43 : Latin America Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 44 : Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 45 : Latin America Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 46 : Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 47 : Latin America Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 48 : Latin America Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 49 : Middle East & Africa Lipid-lowering Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 50 : Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 51 : Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 52 : Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 53 : Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 54 : Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 55 : Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Indication, 2022–2031
  • Figure 56 : Middle East & Africa Lipid-lowering Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 57 : Middle East & Africa Lipid-lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 58 : Company Share Analysis, 2021

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Transparency
Price: $5795

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS